IL166522A0 - Combination of zd6474 an inhibitor of the vascularendothelial growth factor receptor with radiother apy in the treatment of cancer - Google Patents

Combination of zd6474 an inhibitor of the vascularendothelial growth factor receptor with radiother apy in the treatment of cancer

Info

Publication number
IL166522A0
IL166522A0 IL16652205A IL16652205A IL166522A0 IL 166522 A0 IL166522 A0 IL 166522A0 IL 16652205 A IL16652205 A IL 16652205A IL 16652205 A IL16652205 A IL 16652205A IL 166522 A0 IL166522 A0 IL 166522A0
Authority
IL
Israel
Prior art keywords
radiother
apy
cancer
inhibitor
treatment
Prior art date
Application number
IL16652205A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218525A external-priority patent/GB0218525D0/en
Priority claimed from GB0307560A external-priority patent/GB0307560D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL166522A0 publication Critical patent/IL166522A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16652205A 2002-08-09 2005-01-26 Combination of zd6474 an inhibitor of the vascularendothelial growth factor receptor with radiother apy in the treatment of cancer IL166522A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0218525A GB0218525D0 (en) 2002-08-09 2002-08-09 Combination therapy
GB0307560A GB0307560D0 (en) 2003-04-02 2003-04-02 Combination therapy
PCT/GB2003/003388 WO2004014383A1 (en) 2002-08-09 2003-08-05 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer

Publications (1)

Publication Number Publication Date
IL166522A0 true IL166522A0 (en) 2006-01-15

Family

ID=31716921

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16652205A IL166522A0 (en) 2002-08-09 2005-01-26 Combination of zd6474 an inhibitor of the vascularendothelial growth factor receptor with radiother apy in the treatment of cancer

Country Status (13)

Country Link
US (1) US20050222183A1 (xx)
EP (1) EP1534287A1 (xx)
JP (1) JP2006502132A (xx)
KR (1) KR20050056190A (xx)
CN (1) CN1313094C (xx)
AU (1) AU2003249000B2 (xx)
BR (1) BR0313116A (xx)
CA (1) CA2495487A1 (xx)
IL (1) IL166522A0 (xx)
MX (1) MXPA05001458A (xx)
NO (1) NO20050450L (xx)
NZ (1) NZ537753A (xx)
WO (1) WO2004014383A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2306306T3 (es) 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7160889B2 (en) * 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
UA81619C2 (ru) * 2002-02-01 2008-01-25 Астразенека Аб Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR101089462B1 (ko) 2002-11-04 2011-12-07 아스트라제네카 아베 Ｓｒｃ 티로신 키나제 억제제로서의 퀴나졸린 유도체
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
KR20120093411A (ko) * 2003-07-10 2012-08-22 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
JP4945133B2 (ja) * 2006-01-19 2012-06-06 富士フイルムＲｉファーマ株式会社 ４−フェノキシキナゾリン誘導体放射性化合物
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
CN106317022A (zh) * 2015-06-25 2017-01-11 中美华世通生物医药科技（武汉）有限公司 化合物的制备方法和用途
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2306306T3 (es) * 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.

Also Published As

Publication number Publication date
CA2495487A1 (en) 2004-02-19
KR20050056190A (ko) 2005-06-14
CN1313094C (zh) 2007-05-02
WO2004014383A1 (en) 2004-02-19
BR0313116A (pt) 2005-07-05
NZ537753A (en) 2008-04-30
NO20050450L (no) 2005-05-02
US20050222183A1 (en) 2005-10-06
CN1674905A (zh) 2005-09-28
AU2003249000B2 (en) 2007-04-05
EP1534287A1 (en) 2005-06-01
MXPA05001458A (es) 2005-06-06
AU2003249000A1 (en) 2004-02-25
JP2006502132A (ja) 2006-01-19

Similar Documents

Publication Publication Date Title
IL166522A0 (en) Combination of zd6474 an inhibitor of the vascularendothelial growth factor receptor with radiother apy in the treatment of cancer
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
AU2003261100A1 (en) Devices delivering therapeutic agents and methods regarding the same
AU2003301662A8 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
EP1482916A4 (en) THERAPY BASED ON SCHWANN CELLS AND PHOSPHODIESTERASE INHIBITORS
AP2005003251A0 (en) New spirocondensed quinazolinones and their use asphosphodiesterase inhibitors.
AU2003235470A8 (en) Predictive markers in cancer therapy
EP1543034A4 (en) TREATMENT AND PROPHYLAXIS WITH 4-1BB BINDING AGENTS
EP1578782A4 (en) COSTIMULATING FACTORIAL THERAPY
EP1490074A4 (en) MIXED CELL GENE THERAPY
AU2003212634A8 (en) Compounds useful in the treatment of cancer
TW551545U (en) Structure of power supply
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
AU2003215257A8 (en) Modified defensins and their use
GB0207411D0 (en) Azole compounds and their therapeutic use
GB0212405D0 (en) Composition and its therapeutic use
GB0207410D0 (en) Compounds and their therapeutic use
PL375561A1 (en) Therapeutic use
AU2003251513A8 (en) Rsk inhibitors and therapeutic uses thereof
AU2003250831A1 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
EP1544295A4 (en) SALT-INDUCIBLE KINASES 2 AND THEIR USE
AU2003231803A8 (en) Treatment of cancer with mefloquire
IL164951A0 (en) The treatment of pain with lfendropil
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use